Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Imm...
November 10 2017 - 12:30PM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, announced today
that analyses of FGFR2b expression and baseline immune signature in
urothelial cancer (UC) samples were featured in a poster
presentation at the Society for Immunotherapy of Cancer (SITC) 32nd
Annual Meeting, being held November 8-12,
2017 in National Harbor, Maryland. A PDF of the
poster, "FGFR2b Expression and Baseline Immune Signature to Guide
FPA144 Development in Urothelial Cancer," will be made available on
the Publications page of the Five Prime
website. Five Prime is developing FPA144, an isoform-selective
antibody, as a targeted immunotherapy for tumors that overexpress
FGFR2b. Five Prime continues to enroll patients in the Phase 1
trial cohort evaluating FPA144 as a treatment for patients with
bladder cancer whose tumors overexpress FGFR2b.
“Profiling FGFR2b expression and baseline tumor-associated
immune cells could help guide our clinical development strategy for
FPA144 in bladder cancer," said Kevin Baker, Ph.D., Senior
Vice President, Development Sciences at Five Prime. “Previously we
showed in a pre-clinical model with moderate FGFR2b expression,
that FPA144 can reprogram the tumor microenvironment making it more
inflammatory. In the same studies, we also showed that FPA144 and
PD-1 blockade have additive anti-tumor effects.”
Five Prime evaluated FGFR2b expression in 387 archival primary
early stage UC samples and previously reported that >10% had
overexpression of FGFR2b by immunohistochemistry (IHC) with
intensity level of at least 1+. The research team selected 32
archival UC cases with a range of FGFR2b expression (62% were
FGFR2b positive) and characterized baseline immune composition in
the tumor microenvironment and the relationship with FGFR2b
expression to potentially guide FPA144 development in combination
with other therapies.
The results from the selected cases suggest that FGFR2b is
expressed in all immune subtypes of UCs, but the expression level
varies. The highest level of expression is in inflamed and more
proliferative UCs. The Company plans to evaluate additional
archival UC tissues from patients with more advanced metastatic
disease to determine if there is an association of FGFR2b
expression with baseline immune signature in late-stage patient
tumors.
About Five Prime Five Prime Therapeutics,
Inc. discovers and develops innovative therapeutics to improve
the lives of patients with serious diseases. Five Prime's
comprehensive discovery platform, which encompasses virtually every
medically relevant extracellular protein, positions it to explore
pathways in cancer, inflammation and their intersection in
immuno-oncology, an area with significant therapeutic potential and
a growing focus of the company's R&D activities. Five Prime has
entered into strategic collaborations with leading global
pharmaceutical companies and has promising product candidates in
clinical and late preclinical development. For more information,
please visit www.fiveprime.com. Cautionary Note on
Forward-looking Statements This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "may,"
"will," "expect," "plan," "anticipate," "estimate," "intend" and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements are based on Five Prime's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Factors that may cause actual results to differ from
those expressed or implied in the forward-looking statements in
this press release are discussed in Five Prime's filings with
the U.S. Securities and Exchange Commission, including the
"Risk Factors" contained therein. Except as required by law, Five
Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
CONTACT: Derek Cole Investor Relations
Advisory Solutions 720-785-4497 derek.cole@iradvisory.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024